Media coverage about Auris Medical Holding AG (NASDAQ:EARS) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Auris Medical Holding AG earned a news impact score of 0.20 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.0647769011088 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern’s analysis:

EARS has been the topic of several recent research reports. ValuEngine lowered shares of Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Roth Capital reissued a “buy” rating and issued a $5.00 price target on shares of Auris Medical Holding AG in a report on Saturday, July 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $3.42.

Shares of Auris Medical Holding AG (NASDAQ EARS) traded up 2.7200% during midday trading on Monday, reaching $0.7704. 10,712 shares of the company’s stock were exchanged. Auris Medical Holding AG has a 12-month low of $0.60 and a 12-month high of $5.45. The stock’s 50 day moving average is $0.81 and its 200-day moving average is $0.82. The stock’s market cap is $34.15 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.09. On average, equities analysts expect that Auris Medical Holding AG will post ($0.72) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Auris Medical Holding AG (NASDAQ:EARS) Earning Somewhat Positive News Coverage, Accern Reports” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with Analyst Ratings Network's FREE daily email newsletter.